Ticker Details
Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
IPO Date:	October 5, 2001
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.13B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 3.18%
Avg Daily Range (30 D):	$0.42 | 1.75%
Avg Daily Range (90 D):	$0.35 | 1.47%

Institutional Daily Volume
Avg Daily Volume:	.86M
Avg Daily Volume (30 D):	.86M
Avg Daily Volume (90 D):	.9M

Trade Size
Avg Trade Size (Sh.):	146
Avg Trade Size (Sh.) (30 D):	60
Avg Trade Size (Sh.) (90 D):	61

Institutional Trades
Total Institutional Trades:	2,518
Avg Institutional Trade:	$2.76M
Avg Institutional Trade (30 D):	$4.05M
Avg Institutional Trade (90 D):	$3.23M
Avg Institutional Trade Volume:	.21M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.64M
Avg Closing Trade (30 D):	$6.89M
Avg Closing Trade (90 D):	$5.61M
Avg Closing Volume:	270.75K

News

Mar 11, 2026 @ 11:26 AM Catalyst Pharmaceuticals: Exceptional Fundamentals... Source: Gurufocus

Dec 31, 2025 @ 4:06 PM Catalyst Pharmaceuticals Executive Cashes Out 10,9... Source: Sara Appino

Nov 4, 2025 @ 6:31 AM Five-year data of AGAMREE® (vamorolone) in pati... Source: Santhera Pharmaceuticals

Nov 4, 2025 @ 6:31 AM Fünfjahresdaten zu AGAMREE® (Vamorolon) bei ... Source: Santhera Pharmaceuticals

Aug 26, 2025 @ 11:12 PM UPDATED- Catalyst Pharmaceuticals Announces Settle... Source: Catalyst Pharmaceuticals, Inc.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$1.75	$.43	$1.75
Diluted EPS	$1.68	$.41	$1.68
Revenue	$588.99M	$152.61M	$588.99M
Gross Profit	$501.74M	$126.54M	$501.74M
Net Income / Loss	$214.33M	$52.7M	$214.33M
Operating Income / Loss	$257.78M	$61.85M	$257.78M
Cost of Revenue	$87.25M	$26.07M	$87.25M
Net Cash Flow	$191.62M	$19.28M	$191.62M
PE Ratio	14.77